| Contents | 6 |
---|
| Contributors | 8 |
---|
| Introduction: Clinical Immunomics | A New Paradigm for Translational Research |
---|
| References | 17 |
| Integrative Systems Approaches to Study Innate Immunity | 18 |
---|
| 1 Transcriptome Data Sets and the Macrophage Transcriptional Network | 21 |
| References | 27 |
| Immunomics: At the Forefront of Innate Immunity Research | 31 |
---|
| 1 Introduction | 32 |
| 2 Cytokines | 32 |
| 2.1 Interferons | 32 |
| 2.2 Interleukins (ILs) | 33 |
| 2.2.1 Traditional IL-1 Cytokines | 34 |
| 2.2.2 Novel IL-1 Cytokines | 35 |
| 3 Cytokine Receptors | 35 |
| 3.1 IL-1 Receptors | 35 |
| 3.2 Toll-Like Receptors | 36 |
| 3.2.1 Identification of Lps Locus | 37 |
| 4 TIR Signalling Pathways (Downstream Components) | 39 |
| 4.1 MyD88 | 39 |
| 4.2 IRAKs | 41 |
| 4.3 TRAFs | 42 |
| 4.4 NF-kappaB/I-kappaBs | 42 |
| 4.5 IKKs | 43 |
| 5 Identification of Key Components of TIR Signalling | 44 |
| 5.1 Methods for Identifying Novel Components of Signalling Pathway | 44 |
| 5.2 cDNA Library Screening as a Powerful Tool to Explore Signalling Networks | 44 |
| 6 Concluding Remarks | 47 |
| References | 48 |
| Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety | 55 |
---|
| 1 Introduction | 55 |
| 2 Defining the Immunome | 56 |
| 2.1 How Large Is the Immunome? | 57 |
| 3 Steps in the Development of an Epitope-Based IDV | 57 |
| 3.1 Select Protein Antigens of Interest | 57 |
| 3.2 Identifying B Cell Antigens | 59 |
| 3.3 Identifying T Cell Antigens | 59 |
| 3.3.1 In Vitro Assays: Peptide Binding Assays | 60 |
| 3.3.2 In Vitro Assays: Measuring T Cell Responses | 60 |
| 3.4 Select Delivery Vehicle and Adjuvant | 61 |
| 3.5 Animal Model for Vaccine Efficacy | 62 |
| 3.6 Challenge Studies | 63 |
| 3.7 Clinical Development | 63 |
| 4 Epitope Mapping Tools for IDV | 64 |
| 4.1 EpiMatrix: T cell Epitope Mapping for IDV | 64 |
| 4.2 ClustiMer: Finding Promiscuous T cell Epitopes | 65 |
| 5 Additional Vaccine Design Tools | 66 |
| 5.1 Conservatrix: Finding Conserved T Cell Epitopes | 66 |
| 5.2 EpiAssembler: Immunogenic Consensus Sequence Epitopes | 67 |
| 5.3 Eliminating Cross-Reactivity (BlastiMer) | 68 |
| 5.4 Vaccine CAD: Aligning Epitopes | 69 |
| 5.5 HLA Coverage for IDV | 70 |
| 5.6 Aggregatrix: Aggregation of Epitopes into the Ideal IDV | 70 |
| 5.7 Individualized T Cell Epitope Measure (iTEM) | 72 |
| 5.8 Anticipating Processing and Presentation | 72 |
| 6 Methods of Confirming IDV | 73 |
| 6.1 Two Case Studies | 73 |
| 6.1.1 Bacterial (Tularemia) | 73 |
| 6.1.2 Therapeutic HPV Vaccine | 74 |
| 7 Advantages and Disadvantages of IDV | 75 |
| 8 Future Research | 76 |
| 9 Conclusion | 77 |
| References | 78 |
| Immunodeficiencies and Immunome: Diseases and Information Services | 86 |
---|
| 1 ImmunoDeficiency Resource (IDR) | 90 |
| 2 Immunodeficiency Diagnostics Registry (IDdiagnostics) | 91 |
| 3 PIDexpert | 92 |
| 4 Immunodeficiency Mutation Databases, IDbases | 93 |
| 4.1 Using the IDbases | 95 |
| 5 Genotype- Phenotype Correlations | 95 |
| 6 Immunome | 96 |
| References | 98 |
| Immunomics of Immune Rejection | 101 |
---|
| 1 Introduction | 102 |
| 2 Relevance of Tumor-Specific Immune Responses in Humans | 102 |
| 3 Genetic Variables that May Affect the Ability of the Host to Control Cancer Growth | 104 |
| 4 Cancer Cell Biology as the Orchestrator of the Host Immune Response | 105 |
| 5 The Study of the Requirements for Immune Rejection Within the Target Organ | 109 |
| References | 112 |
| Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells | 120 |
---|
| 1 Pathogenesis of Mastocytosis and Classification | 120 |
| 2 Current treatment options for patients with systemic mastocytosis | 122 |
| 3 Expression of Molecular Targets on the Surface of Neoplastic Cells | 123 |
| 4 Signal Transduction-Associated Targets in Neoplastic Mast Cells | 126 |
| 5 Molecular Targets that Play a Role in Growth or Survival of Mast Cells | 128 |
| 6 Mast Cell-Derived Effector Molecules as Targets of Therapy | 129 |
| 7 Targeting of Mast Cell Progenitors and Neoplastic Stem Cells in Mastocytosis | 130 |
| 8 Concluding Remarks | 131 |
| References | 131 |
| Structure, Allergenicity, and Cross-Reactivity of Plant Allergens | 139 |
---|
| 1 Introduction | 139 |
| 2 Protein Families of Plant Allergens | 140 |
| 2.1 The Prolamin Superfamily | 142 |
| 2.2 Profilins | 145 |
| 2.3 Bet v 1-Related Allergens | 146 |
| 2.4 Seed Storage Globulins | 147 |
| 2.5 Expansins and Expansin-Related Allergens | 148 |
| 2.6 Polcalcins | 149 |
| 3 Common Molecular Properties of Allergens | 150 |
| 3.1 Properties of Food Allergens | 151 |
| 3.2 Properties of Pollen Allergens | 152 |
| 4 Sequences, Structures, and Cross-Reactivity | 153 |
| 5 Protein Family Membership and Prediction of Allergenicity | 154 |
| 6 Concluding Remarks | 155 |
| References | 156 |
| The Live Basophil Allergen Array (LBAA): A Pilot Study | 164 |
---|
| 1 Live Basophil Allergen Array | 164 |
| 2 A Short History of Tests for Allergy | 165 |
| 2.1 Skin Prick Tests and Specific IgE Determination | 165 |
| 2.2 Basophil Activation Tests | 166 |
| 2.3 Allergen Microarray Tests: The Next Generation? | 167 |
| 3 Immunobiology of IgE-Dependent Basophil Activation | 168 |
| 3.1 The High-Affinity IgE Receptor FcepsivRI | 168 |
| 3.2 Lipid Rafts and Basop
|